Published in Cancer Weekly, June 5th, 2006
Under the terms of the agreement, Cytogen will no longer pay Berlex a royalty on QUADRAMET sales in exchange for a one-time cash payment of $6 million and the issuance of 623,441 shares of Cytogen common stock at a price of $3.21 per share to Berlex. The transaction is subject to certain closing conditions and is expected to close within 90 days.
As additional consideration, Cytogen will also pay Berlex one-time, sales-based milestone payments of $3.34 million and $5.01 million the first time...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.